Adjuvant therapy with GnRH agonists/tamoxifen in breast cancer should be a good council for patients with hormone receptor-positive tumours and wish to preserve fertility

Franco, J.G.; Oliveira, J.B.A.; Petersen, C.G.; Mauri, A.L.; Baruffi, Ricardo L.R.; Cavagna, M.

doi:10.1016/j.mehy.2011.12.015

Cited by 9 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this case an aromatase inhibitor (e.g. letrozole) should be administered during ovarian stimulation to avoid the possible negative effects of high estrogen levels (Franco et al, 2012;Linkeviciute et al, 2014).…”

Section: Gnrh Analogues For Fertility Preservation In Female Patients...mentioning

confidence: 99%

GnRH and GnRH receptors in the pathophysiology of the human female reproductive system

Maggi

Cariboni

Marelli

et al. 2015

Hum. Reprod. Update

184

118

View full text Add to dashboard Cite

show abstract

Section: Gnrh Analogues For Fertility Preservation In Female Patients...mentioning

confidence: 99%

GnRH and GnRH receptors in the pathophysiology of the human female reproductive system

Maggi

Cariboni

Marelli

et al. 2015

Hum. Reprod. Update

184

118

View full text Add to dashboard Cite

show abstract

“…Use of gonadotrophin-releasing hormone agonists (GnRHa) with or without tamoxifen has been shown to be at least as effective as adjuvant chemotherapy at preventing recurrence of the disease in this population of women (reviewed in [17]). Although these therapies affect fertility while being taken, once the treatment course is completed, pregnancy should be possible as long as the patient remains premenopausal.…”

Section: Cancer Therapy and The Ovarymentioning

confidence: 99%

Uses of anti-Müllerian hormone (AMH) measurement before and after cancer treatment in women

Dunlop¹,

Anderson²

2015

Maturitas

View full text Add to dashboard Cite

“…62 In this patient population, adjuvant therapy with GnRH agonists and tamoxifen is also associated with the preservation of reproductive function. 64,65 Aromatase inhibitors (AI) have been in clinical use for two decades, showing improved clinical outcomes in postmenopausal and premenopausal patients with metastatic breast cancer. [66][67][68] However, a high proportion of patients with metastatic disease develops endocrine resistance leading to disease progression within 12−24 months.…”

Section: T U M O R H E T E Ro G E N E I T Y I N T H E E R a O F P R Ec I S I O N M E D I C I N Ementioning

confidence: 99%

Breast Cancer Treatment in the Era of Precision Medicine

2020

healthbook TIMES Onco Hema

View full text Add to dashboard Cite

Worldwide, breast cancer is the most common cancer in females, with an annual incidence rate of 80-113 cases per 100,000 women. 1 The incidence has increased through recent decades, but the mortality rate has steadily dropped over the last 30 years. 2 Rising incidence is attributed to a combination of better diagnostic methods, lifestyle changes, hormonal replacement therapies, improved screening initiatives, and earlier detection. 3 The declining mortality rate is also associated with screening, together with modernized treatment options, including surgery, chemotherapy, targeted therapy, and radiotherapy. Today, 85% of patients with a breast cancer diagnosis can be cured with multimodal therapy. 4 However, while the aim of treatment is to cure, quality of life and prevention of acute and late treatment-associated toxicity is paramount to the decision process. 5 The St. Gallen Consensus defines four clinically relevant subtypes of breast cancer: luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-enriched, and triple-negative disease (TNBC) subtypes (Table 1). This basic classification is predominantly based on immunochemistry (IHC) markers, including estrogen receptor (ER), progesterone receptor (PR), ERBB2/HER2, and Ki-67. These clinically established, yet simple targets generally correlate with the intrinsic subtypes and still help to guide treatment decisions today. However, through whole-genome sequencing, single-cell analysis, and proteomics, new targets are on the horizon to improve treatment decision making and outcomes. 6 In the era of precision medicine, it is generally accepted that breast cancer is characterized beyond ER/PR/HER2; each subtype requires specific treatment regimens, thus necessitating the evolution of the breast cancer treatment landscape. Recent data from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) Study demonstrated

show abstract

Adjuvant therapy with GnRH agonists/tamoxifen in breast cancer should be a good council for patients with hormone receptor-positive tumours and wish to preserve fertility

Cited by 9 publications

References 22 publications

GnRH and GnRH receptors in the pathophysiology of the human female reproductive system

GnRH and GnRH receptors in the pathophysiology of the human female reproductive system

Uses of anti-Müllerian hormone (AMH) measurement before and after cancer treatment in women

Breast Cancer Treatment in the Era of Precision Medicine

Contact Info

Product

Resources

About